SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI

por Sattar, Abdul, Thommes, Pia, Payne, Lloyd, Warn, Peter, Vickers, Richard J.
Publicado 2015

Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin

por Thorpe, Cheleste M., Kane, Anne V., Chang, Justin, Tai, Albert, Vickers, Richard J., Snydman, David R.
Publicado 2018

Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile

por Collins, Deirdre A, Wu, Yuan, Tateda, Kazuhiro, Kim, Hee-Jung, Vickers, Richard J, Riley, Thomas V
Publicado 2020

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection

por Bassères, Eugénie, Endres, Bradley T., Khaleduzzaman, Mohammed, Miraftabi, Faranak, Alam, M. Jahangir, Vickers, Richard J., Garey, Kevin W.
Publicado 2016

Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids

por Qian, Xi, Yanagi, Karin, Kane, Anne V., Alden, Nicholas, Lei, Ming, Snydman, David R., Vickers, Richard J., Lee, Kyongbum, Thorpe, Cheleste M.
Publicado 2020

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-infer...

por Vickers, Richard J, Tillotson, Glenn S, Nathan, Richard, Hazan, Sabine, Pullman, John, Lucasti, Christopher, Deck, Kenneth, Yacyshyn, Bruce, Maliakkal, Benedict, Pesant, Yves, Tejura, Bina, Roblin, David, Gerding, Dale N, Wilcox, Mark H
Publicado 2017